4 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 3 Phase 1, 3 Phase 2, 2 Not applicable, 2 Phase 4, 1 Early Phase 1.
Follow Parkinson Disease Psychosis: new trials by email Literature Review of Parkinson Disease Psychosis trials Research Report on Parkinson Disease Psychosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Food and Age on the Pharmacokinetics of LY03017 LY03017 - Alzheimer's Disease Psychosis, Parkinson Disease Psychosis | Phase 1 | Not yet recruiting | Luye Pharma Group Ltd. | 26 | 2025-02-01 | 2025-01-27 |
| Bioequivalence Study of Pimavanserin 34 mg Capsule Pimavanserin 34 mg, NUPLAZID 34 MG Oral Capsule - Parkinson Disease Psychosis | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 32 | 2024-01-11 | 2024-06-10 |
| A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 FB418 - Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Recruiting | 1ST Biotherapeutics, Inc. | 64 | 2023-12-20 | 2024-12-02 |
| Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis AGB101 - Parkinson Disease Psychosis | Phase 2 | Active not recruiting | Johns Hopkins University | 30 | 2023-09-28 | 2026-10-07 |
| Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases Pimavanserin - Neurodegenerative Diseases, Parkinson Disease | Phase 4 | Recruiting | Vanderbilt University Medical Center | 75 | 2023-01-23 | 2026-08-07 |
| A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis Iloperidone - Parkinson Disease Psychosis | Phase 2 | Withdrawn | Vanda Pharmaceuticals | 2022-06-01 | 2024-03-21 | |
| Hallucinations in Parkinson's Disease Clinical and neuropsychological assessments, Induction of PH and associated bodily states, Resting-state fMRI acquisition - Parkinson Disease Psychosis | Not applicable | Unknown | Olaf Blanke | 40 | 2020-08-17 | 2020-10-19 |
| Presence Hallucination in Parkinson's Disease Brain changes triggered by PH induction in Parkinson's disease patients with presence hallucinations - Parkinson Disease Psychosis | Not applicable | Unknown | Olaf Blanke | 10 | 2020-08-17 | 2020-10-08 |
| Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis Pimavanserin - Parkinson Disease Psychosis | Phase 4 | Completed | ACADIA Pharmaceuticals Inc. | 29 | 2020-02-10 | 2025-01-14 |
| Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD) Observation of minor phenomena - Parkinson Disease, Parkinson Disease Psychosis | Completed | University of Rochester | 38 | 2019-04-25 | 2024-03-08 | |
| SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis Saracatinib, Placebo Oral Tablet - Parkinson Disease Psychosis | Early Phase 1 | Unknown | King's College London | 30 | 2019-04-11 | 2019-08-13 |
| The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study Real-world, non-interventional - Parkinson Disease Psychosis | Terminated | ACADIA Pharmaceuticals Inc. | 764 | 2017-03-30 | 2021-08-06 | |
| A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis SEP-363856, Placebo capsule - Parkinson Disease Psychosis | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 39 | 2016-12-31 | 2024-07-05 |
Hallucinations (3) · Parkinson Disease (2) · Amyotrophic Lateral Sclerosis (1) · Delusions (1) · Neurodegenerative Diseases (1) · Psychotic Disorders (1)
Nervous System Diseases (5) · Central Nervous System Diseases (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Perceptual Disorders (3) · Signs and Symptoms (3) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Movement Disorders (2) · Neurodegenerative Diseases (2) · Parkinsonian Disorders (2) · Synucleinopathies (2) · Behavior (1) · Behavioral Symptoms (1)
pimavanserin (3) · Levetiracetam (1) · Magnetic Resonance Spectroscopy (1) · SEP-363856 (1) · iloperidone (1) · saracatinib (1)
ACADIA Pharmaceuticals Inc. (2) · Olaf Blanke (2) · 1ST Biotherapeutics, Inc. (1) · Humanis Saglık Anonim Sirketi (1) · Johns Hopkins University (1) · King's College London (1) · Luye Pharma Group Ltd. (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · University of Rochester (1) · Vanda Pharmaceuticals (1) · Vanderbilt University Medical Center (1)
United States (7) · Switzerland (2) · China (1) · India (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Olaf Blanke (2) · Arnold Bakker, Ph.D. (1) · Ciaran Considine, PhD (1) · Mitul Mehta (1) · Richard Darby, MD (1)